Posted by Michael Wonder on 12 Feb 2025
Ganaxolone for the treatment of patients 2 years of age and older with seizures caused by CDKL5 deficiency disorder
12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of patients 2 years of age and older with seizures caused by CDKL5 deficiency disorder.
Ganaxolone is not recommended for use as an add-on treatment for patients 2-17 years of age and adults who turn 18 while on treatment with seizures caused by cyclin dependent kinase‑like 5 deficiency disorder.
